<DOC>
	<DOCNO>NCT00838227</DOCNO>
	<brief_summary>This open label 8-week trial modafinil 400 mg daily add stable antipsychotic regimen evaluate effect modafinil cognition , sedation , weight patient chronic schizophrenia . We hypothesize modafinil , wake-promoting agent , lead improve cognition , increase wakefulness , decrease weight patient schizophrenia stable antipsychotic regimen</brief_summary>
	<brief_title>Modafinil Augmentation Chronic Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Diagnostic Statistical ManualIV diagnosis schizophrenia ( subtypes ) , illness duration great three year Auditory visual acuity adequate complete cognitive test Stable dose antipsychotic least 2 week prior entry Good physical health determine complete physical examination , laboratory test , EKG Capacity willingness give write informed consent . Inability read speak English Documented disease central nervous system History intellectual impairment predate onset symptom psychosis ( e.g . mental retardation ) Clinically significant unstable cardiovascular , renal , hepatic , gastrointestinal , pulmonary hematologic condition ; HIV positive Patients antidepressant , include monoamine oxidase inhibitor Uncontrolled hypertension Pregnancy Patients current diagnosis substance dependence Significant history violence History eat disorder Ready discharge within follow 8 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognition</keyword>
	<keyword>Obesity</keyword>
	<keyword>Sedation</keyword>
</DOC>